Clinical-stage Advantage Leverage InGeneron’s clinical-stage cell therapy platform focused on orthopedic conditions to engage with hospital systems and academic centers seeking regenerative medicine trials and updated standard-of-care approaches.

Point-of-Care Model Target healthcare providers and surgical centers interested in same-day, minimally invasive treatments using patient-derived regenerative cells processed at the point of care, highlighting operational efficiencies and patient throughput.

FDA Evidence Base Emphasize the company’s commitment to clinically evidenced therapies and FDA-aligned development to build credibility with payer organizations, hospital procurement, and trial sites seeking well-supported regenerative solutions.

Strategic Partnerships Explore collaborations with large contract research organizations, academic medical centers, and biotechnology partners to accelerate trial enrollment, data generation, and potential co-development opportunities.

Financial Momentum Position capacity for expansion through ongoing or upcoming funding rounds and showcase recent financing history to investors and strategic buyers as a sign of scalable growth and commercialization potential.